Results 81 to 90 of about 2,094 (126)
Some of the next articles are maybe not open access.
Rho (D) Immune Globulin (Human)
JAMA - Journal of the American Medical Association, 1968Rh O (D) immune globulin (RhoGAM) was administered to Rh negative women within 72 hours after they had given birth to Rh positive, ABO compatible infants to prevent Rh immunization. Two studies, differing only in the dose of anti-Rh immune globulin administered, have shown almost complete prevention of Rh immunization whereas in a group of Rh negative ...
William Pollack
exaly +2 more sources
Potential Drug Interaction Between Rho(D) Immune Globulin and Live Virus Vaccine
Nursing for Women's Health, 2014Women often receive Rho(D) immune globulin as well as a live virus vaccine in the immediate postpartum period. The immune globulin product has the potential to interfere with appropriate immune response to the vaccine. Here we describe our approach to identifying and following up on this often overlooked potential drug interaction.
Amy, Holmes, Debra, Wright
exaly +3 more sources
Biochemical and Biophysical Research Communications, 1970
Abstract A radio-immune assay is described for determining the anti-Rho (D) content of Rho (D) Immune Globulin. The methods for iodination, assay and calculations are described. The significance of this assay is the use of one test dilution and the direct calculation of the concentration of anti-Rho (D).
E B, Paul, V M, Esposito
exaly +3 more sources
Abstract A radio-immune assay is described for determining the anti-Rho (D) content of Rho (D) Immune Globulin. The methods for iodination, assay and calculations are described. The significance of this assay is the use of one test dilution and the direct calculation of the concentration of anti-Rho (D).
E B, Paul, V M, Esposito
exaly +3 more sources
Transfusion Medicine Reviews, 2001
N 1981, IMBACH and colleagues ~ reported the first clinical trial using intravenous immune globulin (IV1G) to treat immune (idiopathic) thrombocytopenic purpura (ITP).~ This study was initiated after the publication of a report that 2 patients with congenital agammaglobulinemia and thrombocytopenia had increased platelet counts after treatment with ...
Sumner Sandler, S G Sandler
exaly +3 more sources
N 1981, IMBACH and colleagues ~ reported the first clinical trial using intravenous immune globulin (IV1G) to treat immune (idiopathic) thrombocytopenic purpura (ITP).~ This study was initiated after the publication of a report that 2 patients with congenital agammaglobulinemia and thrombocytopenia had increased platelet counts after treatment with ...
Sumner Sandler, S G Sandler
exaly +3 more sources
ANTIBODIES TO HEPATITIS A AND B VIRUS ANTIGENS IN Rho (D) IMMUNE GLOBULIN
Lancet, The, 1985R J Gerety, Edward Tabor
exaly +7 more sources
Blood, 2011
Abstract Abstract 4670 BACKGROUND: Acute hemolytic reactions (AHR) associated with administration of Rho (D) Immune Globulin (RhIG; WinRho® SDF, Cangene Corporation, Winnipeg, Canada) have been infrequently reported during the previous 16 years.
Carmen Muller +3 more
exaly +2 more sources
Abstract Abstract 4670 BACKGROUND: Acute hemolytic reactions (AHR) associated with administration of Rho (D) Immune Globulin (RhIG; WinRho® SDF, Cangene Corporation, Winnipeg, Canada) have been infrequently reported during the previous 16 years.
Carmen Muller +3 more
exaly +2 more sources
Blood, 2005
Abstract The Food and Drug Administration (FDA) licensed Rho(D) immune globulin intravenous (anti-D IGIV) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP). A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or ...
exaly +2 more sources
Abstract The Food and Drug Administration (FDA) licensed Rho(D) immune globulin intravenous (anti-D IGIV) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP). A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or ...
exaly +2 more sources
Transfusion
AbstractBackgroundRho(D) immune globulin (RhIg) is used to reduce RhD alloimmunization in pregnancy. This study describes potential causes for RhD alloimmunization after the development and implementation of RhIg.Study Design and MethodsThis retrospective descriptive study investigated RhD‐negative patients born in 1965–2005 with anti‐D newly ...
Carolina Bub +2 more
exaly +3 more sources
AbstractBackgroundRho(D) immune globulin (RhIg) is used to reduce RhD alloimmunization in pregnancy. This study describes potential causes for RhD alloimmunization after the development and implementation of RhIg.Study Design and MethodsThis retrospective descriptive study investigated RhD‐negative patients born in 1965–2005 with anti‐D newly ...
Carolina Bub +2 more
exaly +3 more sources